Ascentage Pharma Group International (stock code: 06855) has released its monthly return for the period ended 31 January 2026. The company’s authorized share capital remains at 500,000,000 ordinary shares with a par value of USD 0.0001, totaling USD 50,000.

The number of issued shares (excluding treasury shares) increased to 373,322,192 from 373,321,692 in the preceding month, reflecting the issuance of 500 shares. The applicable public float requirement of 25% was confirmed to be met.

Under the Pre-IPO Share Option Scheme, 500 share options were exercised during the month, generating HKD 5 in proceeds, leaving 2,151,727 options outstanding. The Post-IPO Share Option Scheme had 736,607 options outstanding at month-end with no additional exercise during January. Regarding the 2022 RSU Scheme, up to 1,644,548 shares remain available for issuance, with none issued during the month.

No repurchases, new treasury shares, or other changes were reported. All necessary confirmations regarding the listing and regulatory requirements were fulfilled in compliance with applicable rules.